Taiwan-based Bora Group has agreed to acquire MacroGenics’ contract development and manufacturing organization (CDMO) business and related manufacturing operations for up to $127.5 million.
The deal includes MacroGenics’ biologics manufacturing facility in Maryland (commonly cited as its Elkridge, MD site), along with associated assets, staff, and CDMO service capabilities.
Bora is using the acquisition to expand its global biologics and injectable CDMO footprint, adding U.S.-based capacity and capabilities to its existing manufacturing network in Asia.
For MacroGenics, the transaction is part of a strategy to streamline operations and focus resources on its core R&D and oncology pipeline rather than in‑house commercial-scale manufacturing services.
The consideration structure involves an upfront payment plus potential additional payments (e.g., tied to milestones or closing adjustments), bringing the total deal value to as much as $127.5 million.
Post-transaction, Bora is expected to continue offering contract manufacturing services to MacroGenics under a supply or transition agreement, ensuring continuity of product supply while ownership of the facility and CDMO operations shifts to Bora.